
FTC Renews Challenges Against Improper Patent Listings to Combat High Drug Prices
WASHINGTON, D.C. — The Federal Trade Commission (FTC) has escalated its efforts to address improper patent listings that hinder generic competition and keep drug prices high. On May 21, the …
FTC Renews Challenges Against Improper Patent Listings to Combat High Drug Prices Read More